Clinical Trial Update: The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects [Phase 3]

View source ↗

Summary

Pfizer's bococizumab (PF-04950615) Phase 3 trial in high-risk cardiovascular disease patients was terminated, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• Bococizumab (bococizumab)

Snippet

Sponsor: Pfizer | Conditions: Cardiovascular Disease | Phase 3 | Status: TERMINATED | Results posted: 2018-06-12